Valeria Chu

856 total citations
31 papers, 544 citations indexed

About

Valeria Chu is a scholar working on Hematology, Cardiology and Cardiovascular Medicine and Genetics. According to data from OpenAlex, Valeria Chu has authored 31 papers receiving a total of 544 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Hematology, 16 papers in Cardiology and Cardiovascular Medicine and 6 papers in Genetics. Recurrent topics in Valeria Chu's work include Blood Coagulation and Thrombosis Mechanisms (16 papers), Atrial Fibrillation Management and Outcomes (10 papers) and Platelet Disorders and Treatments (7 papers). Valeria Chu is often cited by papers focused on Blood Coagulation and Thrombosis Mechanisms (16 papers), Atrial Fibrillation Management and Outcomes (10 papers) and Platelet Disorders and Treatments (7 papers). Valeria Chu collaborates with scholars based in United States, Switzerland and Norway. Valeria Chu's co-authors include Robert J. Leadley, Karen Brown, Ross Bentley, Dennis Colussi, Mark H. Perrone, Scott I. Klein, Christopher T. Dunwiddie, Henry W. Pauls, Alfred P. Spada and Charles Kasiewski and has published in prestigious journals such as Nature Biotechnology, Journal of Medicinal Chemistry and The Journal of Infectious Diseases.

In The Last Decade

Valeria Chu

31 papers receiving 508 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Valeria Chu United States 15 177 163 123 100 86 31 544
Michael J. Orwat United States 13 226 1.3× 271 1.7× 181 1.5× 288 2.9× 35 0.4× 16 782
Jan-Erik Nyström Sweden 9 108 0.6× 155 1.0× 129 1.0× 214 2.1× 26 0.3× 17 552
Tsukasa Ishihara Japan 15 93 0.5× 242 1.5× 164 1.3× 109 1.1× 23 0.3× 45 600
Yvonne Pak United States 12 148 0.8× 74 0.5× 143 1.2× 41 0.4× 30 0.3× 17 534
John M. Fevig United States 13 165 0.9× 100 0.6× 173 1.4× 381 3.8× 57 0.7× 21 641
Fukushi Hirayama Japan 16 413 2.3× 224 1.4× 103 0.8× 118 1.2× 16 0.2× 32 639
Jörg Hauptmann Germany 11 196 1.1× 102 0.6× 153 1.2× 93 0.9× 6 0.1× 13 423
H. Narjes Germany 11 55 0.3× 69 0.4× 111 0.9× 75 0.8× 88 1.0× 17 461
Gérard Sanderink France 11 54 0.3× 174 1.1× 243 2.0× 29 0.3× 142 1.7× 17 866
Edward C. Giardino United States 13 137 0.8× 90 0.6× 175 1.4× 174 1.7× 9 0.1× 20 507

Countries citing papers authored by Valeria Chu

Since Specialization
Citations

This map shows the geographic impact of Valeria Chu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Valeria Chu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Valeria Chu more than expected).

Fields of papers citing papers by Valeria Chu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Valeria Chu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Valeria Chu. The network helps show where Valeria Chu may publish in the future.

Co-authorship network of co-authors of Valeria Chu

This figure shows the co-authorship network connecting the top 25 collaborators of Valeria Chu. A scholar is included among the top collaborators of Valeria Chu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Valeria Chu. Valeria Chu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Paccaly, Anne, Annke Frick, Marie‐Laure Ozoux, et al.. (2006). Pharmacokinetic/Pharmacodynamic Relationships for Otamixaban, a Direct Factor Xa Inhibitor, in Healthy Subjects. The Journal of Clinical Pharmacology. 46(1). 45–51. 7 indexed citations
2.
Ozoux, Marie‐Laure, et al.. (2005). Pharmacodynamic markers in the early clinical assessment of otamixaban, a direct factor Xa inhibitor. Thrombosis and Haemostasis. 94(12). 1156–1163. 20 indexed citations
3.
Klein, Scott I., Kevin R. Guertin, Allison L. Zulli, et al.. (2002). Optimization of the β-Aminoester class of factor Xa inhibitors. part 1: P4 and side-Chain modifications for improved In vitro potency. Bioorganic & Medicinal Chemistry Letters. 12(12). 1667–1670. 14 indexed citations
4.
Guertin, Kevin R., Scott I. Klein, Allison L. Zulli, et al.. (2002). Optimization of the β-Aminoester class of factor Xa inhibitors. part 2: Identification of FXV673 as a potent and selective inhibitor with excellent In vivo anticoagulant activity. Bioorganic & Medicinal Chemistry Letters. 12(12). 1671–1674. 45 indexed citations
5.
He, Wei, Barbara Hanney, Michael R. Myers, et al.. (2002). Benzimidazoles and isosteric compounds as potent and selective factor Xa inhibitors. Bioorganic & Medicinal Chemistry Letters. 12(6). 919–922. 6 indexed citations
6.
Rebello, Sam, Charles Kasiewski, Ross Bentley, et al.. (2001). Superiority of Enoxaparin Over Heparin in Combination With a GPIIb/IIIa Receptor Antagonist During Coronary Thrombolysis in Dogs. Thrombosis Research. 102(3). 261–271. 13 indexed citations
7.
Rebello, Sam, Charles Kasiewski, Wei Wang, et al.. (2001). Role of Short-Term Inhibition of Factor Xa by FXV673 in Arterial Passivation: A Study in a Chronic Model of Thrombosis in Conscious Dogs. Journal of Cardiovascular Pharmacology. 38(2). 288–297. 9 indexed citations
8.
Heran, Christopher L., Charles Kasiewski, Jeffrey S. Bostwick, et al.. (2000). Antithrombotic efficacy of RPR208566, a novel factor Xa inhibitor, in a rat model of carotid artery thrombosis. European Journal of Pharmacology. 389(2-3). 201–207. 23 indexed citations
9.
Gong, Yong, Henry W. Pauls, Alfred P. Spada, et al.. (2000). Amido-(propyl and allyl)-hydroxybenzamidines: development of achiral inhibitors of factor Xa. Bioorganic & Medicinal Chemistry Letters. 10(3). 217–221. 9 indexed citations
10.
Gong, Yong, Michael R. Becker, Yong Mi Choi-Sledeski, et al.. (2000). Solid-phase parallel synthesis of azarene pyrrolidinones as factor Xa inhibitors. Bioorganic & Medicinal Chemistry Letters. 10(10). 1033–1036. 13 indexed citations
11.
He, Wei, Barbara Hanney, Michael R. Myers, et al.. (2000). Nonbenzamidine compounds as selective factor xa inhibitors. Bioorganic & Medicinal Chemistry Letters. 10(15). 1737–1739. 10 indexed citations
12.
Chu, Valeria, Karen Brown, Dennis Colussi, et al.. (2000). In Vitro Characterization of a Novel Factor Xa Inhibitor, RPR 130737. Thrombosis Research. 99(1). 71–82. 16 indexed citations
13.
Becker, Michael R., William R. Ewing, Henry W. Pauls, et al.. (1999). Synthesis, SAR and in vivo activity of novel thienopyridine sulfonamide pyrrolidinones as factor Xa inhibitors. Bioorganic & Medicinal Chemistry Letters. 9(18). 2753–2758. 19 indexed citations
14.
Leadley, Robert J., Ross Bentley, Jeffrey S. Bostwick, et al.. (1999). Pharmacodynamic Activity and Antithrombotic Efficacy of RPR120844, a Novel Inhibitor of Coagulation Factor Xa. Journal of Cardiovascular Pharmacology. 34(6). 791–799. 15 indexed citations
15.
Choi-Sledeski, Yong Mi, Michael R. Becker, William R. Ewing, et al.. (1999). Aminoisoquinolines: Design and synthesis of an orally active benzamidine isostere for the inhibition of factor XA. Bioorganic & Medicinal Chemistry Letters. 9(17). 2539–2544. 20 indexed citations
16.
Klein, Scott I., Bruce F. Molino, Valeria Chu, et al.. (1998). Design of a New Class of Orally Active Fibrinogen Receptor Antagonists. Journal of Medicinal Chemistry. 41(14). 2492–2502. 15 indexed citations
17.
Hwang, L H, Pei–Ming Yang, Ming‐Wei Lai, et al.. (1996). Identification of Humoral Antigenic Determinants in the Hepatitis C Virus NS3 Protein. The Journal of Infectious Diseases. 174(1). 173–176. 12 indexed citations
18.
Klein, Scott I., Bruce F. Molino, Robert J. Leadley, et al.. (1996). Non-peptide fibrinogen receptor antagonists based upon a 4-substituted piperidine scaffold. Bioorganic & Medicinal Chemistry Letters. 6(12). 1403–1408. 3 indexed citations
19.
Prior, Christopher P., Valeria Chu, Bernard Cambou, et al.. (1993). Optimization of a Recombinant von Willebrand Factor Fragment as an Antagonist of the Platelet Glycoprotein Ib Receptor. Nature Biotechnology. 11(6). 709–713. 11 indexed citations
20.
Wehrli, Pius A., et al.. (1972). A New Synthesis of 6-Hydroxydopamine. Canadian Journal of Chemistry. 50(18). 3075–3079. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael J. Orwat Breakdown of academic impact, for papers by Jan-Erik Nyström Breakdown of academic impact, for papers by Tsukasa Ishihara Breakdown of academic impact, for papers by Yvonne Pak Breakdown of academic impact, for papers by John M. Fevig Breakdown of academic impact, for papers by Fukushi Hirayama Breakdown of academic impact, for papers by Jörg Hauptmann Breakdown of academic impact, for papers by H. Narjes Breakdown of academic impact, for papers by Gérard Sanderink Breakdown of academic impact, for papers by Edward C. Giardino
Rankless by CCL
2026